Find Clinical Trial

Home » Find Clinical Trials » An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)

An open-label, randomised, phase III Study cOmparing trifLuridine/tipiracil (S 95005) in combination with bevacizumab to capecitabine in combination with bevacizumab in firST-line treatment of patients with metastatIC colorectal cancer who are not candidatE for intensive therapy (SOLSTICE study)

← Back

Study Phase	Phase 3

Therapeutic Area	Cancers

Indication	Solid tumors

Sponsor	Institut de Recherches Internationales Servier (I.R.I.S)

Active substance/ Medical device	TIPIRACIL, TRIFLURIDINE, S095005

Active Substance Code	S095005

Protocol Code	CL3-95005-006

EudraCT Code	2017-004059-22

NCT Code	NCT03869892

Documents and links

Lay summary

Results summary	READ MORE

Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.